Dyadic International 2025 Q3 Earnings Net Loss Widens 871% Amid Strategic Shift

Dyadic International (DYAI) reported Q3 2025 results on November 13, with revenue of $1.16 million beating estimates by $0.04 million but GAAP EPS of -$0.06 missing expectations by $0.02. The company reiterated guidance on revenue sharing from partnerships in 2026 but provided no explicit earnings targets, aligning with its strategic focus on commercialization.

Revenue

Dyadic’s Q3 revenue totaled $1.16 million, a 40.5% decline year-over-year. Research and development revenue totaled $350,046, while grant revenue reached $814,571. The company attributed the decline to reduced active collaborations and milestone income, offset partially by increased grant funding from the Gates Foundation and CEPI.

Earnings/Net Income

Net loss widened to $1.98 million, or $0.06 per share, representing an 871.2% increase from $203,460 in the prior-year period. The EPS result reflects ongoing operational challenges despite the strategic pivot to commercialization.

Post-Earnings Price Action Review

The stock price of Dyadic International has dropped 3.72% during the latest trading day, has dropped 7.65% during the most recent full trading week, and has tumbled 13.81% month-to-date.

CEO Commentary

Joe Hazelton, President and Chief Operating Officer, emphasized Dyadic’s strategic pivot from R&D to commercial focus, rebranding as Dyadic Applied BioSolutions, and securing a CRISPR license to enhance production capabilities. He highlighted “successful execution of our strategic transformation to a commercial biotech leader,” citing strengthened liquidity via an $4.9M equity offering and $10.4M in cash as of September 30, 2025. Hazelton expressed optimism about scalable growth, driven by CRISPR-enabled strain optimization, expanding commercial traction in Asia, and key milestones in recombinant protein programs. The tone underscored confidence in positioning Dyadic for “sustainable revenue growth and long-term value creation.”

Guidance

The company anticipates ongoing revenue sharing from Proliant and Inzyme collaborations in 2026, with initial purchase orders for recombinant transferrin and FGF expected by late 2025. It expects sampling for recombinant alpha-lactalbumin and lactoferrin to begin in early 2026, alongside continued optimization of C1 and Dapibus platforms. Forward-looking statements note reliance on grant funding and commercialization progress, with no explicit revenue or EPS guidance provided. The equity offering proceeds will fund working capital, product development, and marketing.

Additional News

Dyadic completed a strategic rebrand to Dyadic Applied BioSolutions, enhancing its commercial focus and launching a redesigned website to bolster engagement. The company secured a non-exclusive CRISPR license from ERS Genomics, expanding its genetic engineering capabilities for strain optimization. Additionally, Dyadic raised $4.9 million through an equity offering in August 2025, strengthening its cash position to $10.4 million as of September 30, 2025.